title: Candidate vaccines for immunotherapy in HIV.
abstract: In this short article we review the immunopathology of HIV infection and delineate the kinds of immune responses seen in acute infection and in long-term nonprogression that are understood to be necessary if the host is to maintain long-term control of the virus. In this context we discuss the potential promise of therapeutic vaccination in HIV infection.
authors.affiliation: Department of Immunology, Imperial College School of Medicine, Chelsea and Westminster Hospital, London, UK. f.gotch@ic.ac.uk
authors.forename: F M
authors.initials: FM
authors.lastname: Gotch
authors.forename: N
authors.initials: N
authors.lastname: Imami
authors.forename: G
authors.initials: G
authors.lastname: Hardy
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D000208:Acute Disease; D019380:Anti-HIV Agents / Q000276:immunology / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D003131:Combined Modality Therapy; D016207:Cytokines / Q000187:drug effects / Q000276:immunology / Q000627:therapeutic use; D018450:Disease Progression; D016655:HIV Core Protein p24 / Q000276:immunology / Q000627:therapeutic use; D015658:HIV Infections / Q000276:immunology* / Q000628:therapy* / Q000821:virology; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000592:standards; D018579:Patient Selection; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D016915:AIDS Vaccines; D019380:Anti-HIV Agents; D016207:Cytokines; D016655:HIV Core Protein p24; C053473:VaxSyn HIV-1 (gp160) vaccine; C065031:p24-VLP vaccine; C105086:remune